WO2010043849A1 - Process for the preparation of rufinamide - Google Patents
Process for the preparation of rufinamide Download PDFInfo
- Publication number
- WO2010043849A1 WO2010043849A1 PCT/GB2009/002419 GB2009002419W WO2010043849A1 WO 2010043849 A1 WO2010043849 A1 WO 2010043849A1 GB 2009002419 W GB2009002419 W GB 2009002419W WO 2010043849 A1 WO2010043849 A1 WO 2010043849A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- azide
- rufinamide
- methyl
- iii
- Prior art date
Links
- 0 *Cc(c(F)ccc1)c1F Chemical compound *Cc(c(F)ccc1)c1F 0.000 description 1
- XVEURJOWGBWEPY-UHFFFAOYSA-N COC(c1c[n](Cc(c(F)ccc2)c2F)nn1)=O Chemical compound COC(c1c[n](Cc(c(F)ccc2)c2F)nn1)=O XVEURJOWGBWEPY-UHFFFAOYSA-N 0.000 description 1
- POGQSBRIGCQNEG-UHFFFAOYSA-N NC(c1c[n](Cc(c(F)ccc2)c2F)nn1)=O Chemical compound NC(c1c[n](Cc(c(F)ccc2)c2F)nn1)=O POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Definitions
- the present invention relates to an improved process for the preparation of rufinamide.
- Rufinamide is an anticonvulsant medication. It has been used in combination with other medication and therapy to treat Lennox-Gastaut spasms and various other seizure disorders.
- Rufinamide a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.
- the chemical name for rufinamide is 1- (2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide (formula I), and it is represented by the following structure.
- 2,6-difluorobenzylchloride of formula Ii and sodium azide are reacted in the presence of DMSO to obtain 2-(azidomethyI)-1 ,3-difluorobenzene of formula III, which is then treated with 2-propioIic acid to give a carboxylic acid intermediate which on further reaction with methanol in the presence of sulfuric acid yields methyl 1-(2,6- difluorobenzyl)-1 H-1 ,2,3-triazo!e-4-carboxylate intermediate of formula IV. This intermediate is then isolated and further reacted with methanolic ammonia to yield rufinamide of formula I.
- US 4,789,680 also discloses the preparation of rufinamide by reacting 2,6- difluorobenzyl azide of formula III with propiolic acid to give the corresponding carboxylic acid intermediate which is then treated with thionyl chloride and subsequently with ammonia to obtain rufinamide.
- W 01998/002423 discloses a process for preparation of rufinamide which involves reacting 2,6-difluorobenzylazide with 2-chloroacrylonitrile.
- the synthesis of rufinamide described in the earlier processes involves the isolation of intermediates at each step, and then subjection of the isolated intermediates to new reagents which require different conditions, solvents, temperature, etc. Due to the multistep extractive workup procedures, there is an increase in the processing time period along with an increase in the usage of solvent. Such discontinuous processes lead to lower yield, as product is lost during each isolation step and increases the effluent load. Further, the synthesis described in the prior art involves the use of environmentally unfriendly organic solvents. It is therefore evident that there is a need for an alternative process for synthesizing rufinamide which avoids multiple isolation steps, the use of multiple reaction vessels and the use of organic solvent, and which results in a high yield.
- the object of the present invention is to provide an improved process for the preparation of rufinamide.
- Another object of the invention is to provide a process for the preparation of rufinamide which is simple, economical and eco-friendly with reduced reaction times.
- X is chloride and the compound of formula Il has the formula HA.
- X is bromide and the compound of formula Il has the formula HB.
- the azide is an alkali metal azide, an alkyl silyl azide or a phosphoryl azide.
- the alkali metal azide may be sodium azide or potassium azide.
- the alkali metal azide is sodium azide.
- the alkyl silyl azide may have the formula R 3 Si-N3, wherein each R is a Ci to C 6 alkyl group, for example methyl, ethyl, n-propyl, i-propyl, butyl, pentyl or hexyl.
- the alkyl silyl azide is trimethylsilyl azide.
- the azide is a phosphoryl azide, for example having the formula P(O)(OR') 2 N 3 , wherein each R' is a Ci to C ⁇ alkyl group or optionally substituted aryl.
- R' is unsubstituted phenyl.
- the ammonia used in step (iii) may be in the form of gaseous ammonia, liquid ammonia or aqueous ammonia, preferably aqueous ammonia.
- the concentration of the aqueous ammonia ranges from about 20% to about 25%.
- the aqueous ammonia is added dropwise.
- step (i) is carried out at a temperature ranging from about 60 0 C to about 80 0 C, preferably ranging from about 70 0 C to about 75 0 C.
- the reaction time for step (i) ranges from about 25 hours to about 40 hours, and preferably from about 25 hours to about 30 hours.
- step (ii) the methyl propiolate is added to the 2- (azidomethyl)-1 ,3-difluorobenzene intermediate of formula III dropwise at a temperature ranging from about 20 0 C to about 30 0 C (suitably about 25 0 C). Then the temperature may be raised to a temperature ranging from about 50 0 C to about 75 0 C, preferably to a temperature ranging from about 60 0 C to about 65 0 C, and the time required for the step (ii) ranges from about 4 to about 5 hours.
- all the reaction steps are carried out in the presence of water as a solvent.
- water is the only solvent.
- steps (i) to (iii) are carried out without isolation of 2-(azidomethyl)-1,3- difluorobenzene of formula III and without isolation of methyl 1-(2,6-difluorobenzyl)-1 H- 1 ,2,3-triazoie-4-carboxylic acid of formula IV.
- steps (i) to (iii) are carried out without isolation of 2-(azidomethyl)-1,3- difluorobenzene of formula III and without isolation of methyl 1-(2,6-difluorobenzyl)-1 H- 1 ,2,3-triazoie-4-carboxylic acid of formula IV.
- neither one of these intermediates is isolated from the reaction mixture as a solid.
- the process is a one-pot process. In other words, all the steps that result in rufinamide in the process of the present invention are carried out in a single reaction vessel.
- telomere prepared according to the process of the present invention.
- a pharmaceutical composition comprising rufinamide prepared according to the process of the present invention together with one or more pharmaceutically acceptable excipients.
- rufinamide prepared according to the process of the present invention for use in treating epilepsy or subindications thereof.
- a method of treating epilepsy or a subindication thereof comprising administering to a subject in need thereof a therapeutically effective amount of rufinamide prepared according to the process of the present invention.
- the present invention is advantageous as it provides an improved process for preparing rufinamide which process involves the use of methyl propiolate.
- the use of methyl propiolate in a process for preparing rufinamide is carried out in water as a solvent.
- the process is a one-pot process.
- the process may involve reacting 2-(azidomethyl)-1,3-difluorobenzene of formula III with methyl propiolate, to obtain methyl 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4- carboxylic acid of formula IV, and converting the methyl 1-(2,6-difluorobenzyl)-1 H-1 ,2,3- triazole-4-carboxylic acid of formula IV to rufinamide.
- the conversion of methyl 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxylic acid of formula IV to rufinamide may comprise reacting the methyl 1-(2,6-difluorobenzyl)-1H- 1 ,2,3-triazole-4-carboxylic acid of formula IV with ammonia to obtain rufinamide.
- the 2-(azidomethyl)-1,3-difluorobenzene of formula III may have been prepared by reacting a 2,6-difluorobenzylhalide of formula II, wherein X is chloride, bromide or iodide, with an azide to obtain the 2-(azidomethyl)-1 ,3-difluorobenzene of formula 111.
- the process of the present invention involves the synthesis of rufinamide and may employ water as a solvent which contributes to green chemistry.
- the present invention describes a practical, economical and efficient synthesis for the preparation of rufinamide. This process is particularly advantageous in comparison with known methods because the reaction may be carried out without isolating the intermediates formed by the preceding step.
- the process of the present invention eliminates the risk of handling hazardous chemicals, the enhanced cost associated with multiple reactors, and it reduces the reaction time and cleanup, thus making the process more industrially viable.
- the present invention provides a process for the preparation of rufinamide of formula I, which process comprises: (a) reacting 2,6- difluorobenzylchloride of formula HA
- the process is carried out without isolation of 2-(azidomethyl)-1 ,3- difluorobenzene and without isolation of methyl 1-(2,6-difluorobenzyl)-1H-1 ,2,3-triazole- 4-carboxylic acid.
- the process is carried out as a one-pot process. Alternatively, the process may be carried out with isolation of the intermediates.
- water is the solvent in each of steps (i), (ii) and (iii).
- Water is advantageous over the environmentally-unfriendly organic solvents as used in the prior art. Further, the use of water reduces the production cost, simplifies the work-up and minimizes the effluent disposal problem.
- step (a) is carried out at a temperature ranging from about 60 0 C to about 80 0 C, preferably ranging from about 70 0 C to about 75 0 C.
- reaction time to produce the azide intermediate of formula III ranges from about 25 hours to about 40 hours, and preferably from about 25 hours to about 30 hours.
- step (b) the 2-(azidomethyl)-1 ) 3-difluorobenzene intermediate is subjected to a ring closure reaction by adding methyl propiolate dropwise at room temperature (about 25 0 C) and then allowing the temperature to rise to a temperature ranging from about 50 0 C to about 75 0 C, preferably to a temperature ranging from about 60 0 C to about 65 0 C, and the time required for the reaction ranges from about 4 to about 5 hours.
- the amidation reaction of step (c) is carried out using ammonia which may be in the form of gaseous ammonia, liquid ammonia or aqueous ammonia, preferably aqueous ammonia.
- ammonia which may be in the form of gaseous ammonia, liquid ammonia or aqueous ammonia, preferably aqueous ammonia.
- the concentration of the aqueous ammonia ranges from about 20% to about 25%.
- the aqueous ammonia is added dropwise.
- the reaction is preferably carried out at a temperature ranging from about 65 0 C to about 80 0 C, more preferably from about 70 0 C to about 75 0 C.
- reaction contents are cooled to room temperature (about 25 0 C), washed with water and then dried under vacuum to obtain solid rufinamide.
- rufinamide is prepared by isolating the intermediates obtained at each preceding step.
- the invention also relates to the use of rufinamide preferably in the form of pharmaceutical preparations for the treatment of epilepsy and subindications thereof.
- Step B Preparation of methyl 1-(2,6-difluorobenzyl)-1H-1,2,3-tr ⁇ azole-4- carboxylic acid:
- Step C Preparation of rufinamide: A mixture of intermediate obtained from step B (0.0098 mol, 2.5 g), and 20% aqueous ammonia solution (0.196 mol, 15 ml) was added to a 250 ml round bottom flask. The mixture was then stirred at 70 0 C to 75 0 C for 5 to 6 hours. After the completion of reaction, as monitored by TLC, the reaction mixture was cooled to room temperature. The solid obtained was filtered, washed with water and dried under vacuum at 60 0 C to 65 0 C to give a solid product (1.7 g).
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009305255A AU2009305255B2 (en) | 2008-10-13 | 2009-10-09 | Process for the preparation of rufinamide |
JP2011530559A JP2012505191A (en) | 2008-10-13 | 2009-10-09 | Method for producing rufinamide |
NZ591725A NZ591725A (en) | 2008-10-13 | 2009-10-09 | PROCESS FOR THE PREPARATION OF RUFINAMIDE which is also known as 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
US13/063,440 US8183269B2 (en) | 2008-10-13 | 2009-10-09 | Process for the preparation of rufinamide |
CA2736703A CA2736703A1 (en) | 2008-10-13 | 2009-10-09 | Process for the preparation of rufinamide |
EP09744712A EP2334653A1 (en) | 2008-10-13 | 2009-10-13 | Process for the preparation of rufinamide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2190/MUM/2008 | 2008-10-13 | ||
IN2190MU2008 | 2008-10-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010043849A1 true WO2010043849A1 (en) | 2010-04-22 |
WO2010043849A8 WO2010043849A8 (en) | 2011-06-30 |
Family
ID=41786401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2009/002419 WO2010043849A1 (en) | 2008-10-13 | 2009-10-09 | Process for the preparation of rufinamide |
Country Status (9)
Country | Link |
---|---|
US (1) | US8183269B2 (en) |
EP (1) | EP2334653A1 (en) |
JP (2) | JP2012505191A (en) |
KR (1) | KR20110067022A (en) |
AU (1) | AU2009305255B2 (en) |
CA (1) | CA2736703A1 (en) |
NZ (1) | NZ591725A (en) |
WO (1) | WO2010043849A1 (en) |
ZA (1) | ZA201101836B (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102219752A (en) * | 2011-04-21 | 2011-10-19 | 北京赛科药业有限责任公司 | Novel crystal form D of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
WO2011135105A1 (en) | 2010-04-30 | 2011-11-03 | Laboratorios Lesvi, S.L. | Improved process for preparing rufinamide intermediate |
WO2012025936A2 (en) | 2010-08-25 | 2012-03-01 | Ramamohan Rao Davuluri | Improved process for the preparation of rufinamide |
WO2012032540A1 (en) | 2010-09-06 | 2012-03-15 | Indoco Remedies Limited | Process for preparation of fluorinated triazole compound |
US8183269B2 (en) | 2008-10-13 | 2012-05-22 | Cipla Limited | Process for the preparation of rufinamide |
CN103539750A (en) * | 2012-07-09 | 2014-01-29 | 旭和(天津)医药科技有限公司 | Synthesis process of rufinamide |
WO2014072992A1 (en) | 2012-11-12 | 2014-05-15 | Aarti Industries Limited | A process for preparing triazole compounds |
WO2014120994A1 (en) * | 2013-01-31 | 2014-08-07 | The Johns Hopkins University | Rufinamide and derivatives and their use in modulating the gating process of human voltage-gated sodium channels |
WO2014121383A1 (en) * | 2013-02-11 | 2014-08-14 | Apotex Technologies Inc. | A process for the preparation of rufinamide and intermediates thereof |
CN109438374A (en) * | 2018-10-10 | 2019-03-08 | 凯莱英医药集团(天津)股份有限公司 | Rufinamide is continuously synthesizing to method |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140357871A1 (en) | 2012-01-10 | 2014-12-04 | Lupin Limited | Process for preparation of rufinamide |
KR20190081386A (en) | 2017-12-29 | 2019-07-09 | 강원대학교산학협력단 | Composition for preventing the ischemia stroke disease containing rufinamide |
CN114106211A (en) * | 2021-08-31 | 2022-03-01 | 海南医学院 | Yunnan chanterelle polysaccharide and separation and purification method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4789680A (en) * | 1982-12-23 | 1988-12-06 | Ciba-Geigy Corporation | Aralkyltriazole compounds |
WO1998056772A1 (en) * | 1997-06-10 | 1998-12-17 | Novartis Ag | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL127665A (en) | 1996-07-11 | 2004-03-28 | Novartis Ag | Process for preparing 1-substituted 4-cyano-1,2,3,-triazoles |
NZ591725A (en) | 2008-10-13 | 2012-09-28 | Cipla Ltd | PROCESS FOR THE PREPARATION OF RUFINAMIDE which is also known as 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
-
2009
- 2009-10-09 NZ NZ591725A patent/NZ591725A/en not_active IP Right Cessation
- 2009-10-09 WO PCT/GB2009/002419 patent/WO2010043849A1/en active Application Filing
- 2009-10-09 CA CA2736703A patent/CA2736703A1/en not_active Abandoned
- 2009-10-09 US US13/063,440 patent/US8183269B2/en not_active Expired - Fee Related
- 2009-10-09 AU AU2009305255A patent/AU2009305255B2/en not_active Ceased
- 2009-10-09 JP JP2011530559A patent/JP2012505191A/en active Pending
- 2009-10-13 KR KR1020117006738A patent/KR20110067022A/en not_active Application Discontinuation
- 2009-10-13 EP EP09744712A patent/EP2334653A1/en not_active Withdrawn
-
2011
- 2011-03-10 ZA ZA2011/01836A patent/ZA201101836B/en unknown
-
2014
- 2014-11-28 JP JP2014240724A patent/JP2015096515A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4789680A (en) * | 1982-12-23 | 1988-12-06 | Ciba-Geigy Corporation | Aralkyltriazole compounds |
WO1998056772A1 (en) * | 1997-06-10 | 1998-12-17 | Novartis Ag | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic |
Non-Patent Citations (2)
Title |
---|
See also references of EP2334653A1 * |
SULTAN T. ABU-ORABI ET AL.: "Effect of solvant and reaction time on the products of the 1,3-dipolar cycloaddition of substituted benzyl azides with di-tert-butyl acetylenedicarboxylate", GAZZETTA CHIMICA ITALIANA, vol. 122, 1992, pages 29 - 33, XP008120316 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8183269B2 (en) | 2008-10-13 | 2012-05-22 | Cipla Limited | Process for the preparation of rufinamide |
WO2011135105A1 (en) | 2010-04-30 | 2011-11-03 | Laboratorios Lesvi, S.L. | Improved process for preparing rufinamide intermediate |
US8884026B2 (en) | 2010-04-30 | 2014-11-11 | Laboratorios Lesvi, S.L. | Process for preparing rufinamide intermediate |
JP2013525413A (en) * | 2010-04-30 | 2013-06-20 | ラボラトリオス レスヴィ,エス.エル. | Improved process for the preparation of rufinamide intermediate |
JP2013538208A (en) * | 2010-08-25 | 2013-10-10 | ラオ ダヴルリ,ラマモハン | Improved rufinamide preparation process |
WO2012025936A2 (en) | 2010-08-25 | 2012-03-01 | Ramamohan Rao Davuluri | Improved process for the preparation of rufinamide |
WO2012032540A1 (en) | 2010-09-06 | 2012-03-15 | Indoco Remedies Limited | Process for preparation of fluorinated triazole compound |
CN102219752A (en) * | 2011-04-21 | 2011-10-19 | 北京赛科药业有限责任公司 | Novel crystal form D of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
CN103539750A (en) * | 2012-07-09 | 2014-01-29 | 旭和(天津)医药科技有限公司 | Synthesis process of rufinamide |
WO2014072992A1 (en) | 2012-11-12 | 2014-05-15 | Aarti Industries Limited | A process for preparing triazole compounds |
WO2014120994A1 (en) * | 2013-01-31 | 2014-08-07 | The Johns Hopkins University | Rufinamide and derivatives and their use in modulating the gating process of human voltage-gated sodium channels |
WO2014121383A1 (en) * | 2013-02-11 | 2014-08-14 | Apotex Technologies Inc. | A process for the preparation of rufinamide and intermediates thereof |
CN109438374A (en) * | 2018-10-10 | 2019-03-08 | 凯莱英医药集团(天津)股份有限公司 | Rufinamide is continuously synthesizing to method |
CN109438374B (en) * | 2018-10-10 | 2020-10-30 | 凯莱英医药集团(天津)股份有限公司 | Continuous synthesis method of rufinamide |
Also Published As
Publication number | Publication date |
---|---|
AU2009305255A8 (en) | 2011-08-25 |
ZA201101836B (en) | 2011-10-26 |
US8183269B2 (en) | 2012-05-22 |
JP2015096515A (en) | 2015-05-21 |
AU2009305255A1 (en) | 2010-04-22 |
EP2334653A1 (en) | 2011-06-22 |
US20110207938A1 (en) | 2011-08-25 |
NZ591725A (en) | 2012-09-28 |
JP2012505191A (en) | 2012-03-01 |
AU2009305255B2 (en) | 2014-02-06 |
WO2010043849A8 (en) | 2011-06-30 |
KR20110067022A (en) | 2011-06-20 |
CA2736703A1 (en) | 2010-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009305255B2 (en) | Process for the preparation of rufinamide | |
EP3882237B1 (en) | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide | |
EP2230234B1 (en) | Process for the preparation of rufinamide | |
JP6108112B2 (en) | Improved rufinamide preparation process | |
US7705159B2 (en) | Process for the preparation of letrozole | |
EP2066646B1 (en) | Process for the preparation of pure anastrozole | |
HU203327B (en) | Process for producing fluorinated benzyl-thiazol derivatives and pharmaceutical compositions containing them | |
EP3577099B1 (en) | A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes | |
CZ4299A3 (en) | Process for preparing 1-substituted 4-cyan-1,2,3- triazoles | |
US7368464B2 (en) | Preparation for the production of 1,2,4-triazolylmethyl-oxiranes | |
CN110563659B (en) | Method for preparing 1,2, 3-triazole compound by heterogeneous copper catalysis in one pot | |
JP4502225B2 (en) | Process for producing 5-substituted 2-chloropyridine | |
CN114478411A (en) | Method for synthesizing prothioconazole | |
JP3407088B2 (en) | Method for producing triazole derivative and intermediate thereof | |
EP1471058B1 (en) | Process for producing 1,2,3-triazole compound | |
JP5106574B2 (en) | Method for producing 1-substituted-4-carbamoyl-1,2,4-triazol-5-one derivative | |
WO1988003531A1 (en) | Cardiotonic imidazolylphenylpyrrol-2-ones | |
JPH07300463A (en) | Production of 5-alkoxyhydantoin compound | |
JPH07300464A (en) | Production of 5-alkoxyhydantoin compound | |
PL204392B1 (en) | Method of obtaining 2,2'-(5-(1H-1,2,4-triazol-1-)-ylmethyl)-1,3-phenylene)di(2-methylpropionitrile) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09744712 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2009744712 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009744712 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009305255 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2736703 Country of ref document: CA Ref document number: 475/MUMNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 591725 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 20117006738 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2009305255 Country of ref document: AU Date of ref document: 20091013 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011530559 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13063440 Country of ref document: US |